Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Oncogenic osteomalacia × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cholangiocarcinoma 3 Glioblastoma 2 Upper Tract Urothelial Carcinomas 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Papillomavirus Infections 1 Oncogenic osteomalacia 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Hypophosphatemia 1 Hematologic Neoplasms 1 Glioma 1 Breast Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

infigratinib 1 burosumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03510455 2021-04-08

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated

4 enrolled 28 charts

Oncogenic osteomalacia, Hypophosphatemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡